A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.

IF 3.5 4区 医学 Q1 DERMATOLOGY Acta dermato-venereologica Pub Date : 2024-11-07 DOI:10.2340/actadv.v104.41120
Jui Vyas, Jeffrey R Johns, Faraz M Ali, John R Ingram, Sam Salek, Andrew Y Finlay
{"title":"A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.","authors":"Jui Vyas, Jeffrey R Johns, Faraz M Ali, John R Ingram, Sam Salek, Andrew Y Finlay","doi":"10.2340/actadv.v104.41120","DOIUrl":null,"url":null,"abstract":"<p><p>This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker's Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors. Of 1,717 screened publications, 207 articles including 58,828 patients from >  49 different countries and 41 diseases met the inclusion criteria. The DLQI demonstrated strong test-retest reliability; 43 studies confirmed good internal consistency. Twelve studies were performed using anchors to assess change responsiveness with effect sizes from small to large, giving confidence that the DLQI responds appropriately to change. Forty-two studies tested known-groups validity, providing confidence in construct and use of the DLQI over many parameters, including disease severity, anxiety, depression, stigma, scarring, well-being, sexual function, disease location and duration. DLQI correlation was demonstrated with 119 Patient Reported Outcomes/Quality of Life measures in 207 studies. Only 15% of studies explicitly recruited minority ethnic participants; 3.9% stratified results by race/ethnicity. This review summarizes knowledge concerning DLQI validation, confirms many strengths of the DLQI and identifies areas for further validation.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"104 ","pages":"adv41120"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11559262/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta dermato-venereologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2340/actadv.v104.41120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker's Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors. Of 1,717 screened publications, 207 articles including 58,828 patients from >  49 different countries and 41 diseases met the inclusion criteria. The DLQI demonstrated strong test-retest reliability; 43 studies confirmed good internal consistency. Twelve studies were performed using anchors to assess change responsiveness with effect sizes from small to large, giving confidence that the DLQI responds appropriately to change. Forty-two studies tested known-groups validity, providing confidence in construct and use of the DLQI over many parameters, including disease severity, anxiety, depression, stigma, scarring, well-being, sexual function, disease location and duration. DLQI correlation was demonstrated with 119 Patient Reported Outcomes/Quality of Life measures in 207 studies. Only 15% of studies explicitly recruited minority ethnic participants; 3.9% stratified results by race/ethnicity. This review summarizes knowledge concerning DLQI validation, confirms many strengths of the DLQI and identifies areas for further validation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对描述皮肤科生活质量指数验证方面的 207 项研究进行系统回顾。
本研究系统分析了描述皮肤科生活质量指数(DLQI)验证方面的同行评审出版物,并使用奈克的 "反种族主义批判性评估工具 "评估种族偏见风险。从 1994 年到 2022 年,我们在七个在线数据库中搜索了包含 DLQI 验证数据的文章。研究方法遵循 PRISMA 指南,研究方案在 PROSPERO 中注册,文章由两名评审员独立评审。在筛选出的 1717 篇出版物中,有 207 篇文章符合纳入标准,其中包括来自 49 个不同国家和 41 种疾病的 58828 名患者。DLQI显示出很强的测试-再测可靠性;43项研究证实了良好的内部一致性。有 12 项研究使用锚点来评估变化反应性,其效应大小由小到大,从而使人相信 DLQI 能够对变化做出适当的反应。有 42 项研究测试了已知组的有效性,从而使人们对 DLQI 在疾病严重程度、焦虑、抑郁、耻辱感、瘢痕、幸福感、性功能、发病部位和持续时间等许多参数方面的构建和使用有了信心。在 207 项研究中,DLQI 与 119 项 "患者报告结果"/"生活质量 "测量指标之间存在相关性。只有 15% 的研究明确招募了少数族裔参与者;3.9% 的研究按种族/民族对结果进行了分层。本综述总结了有关 DLQI 验证的知识,确认了 DLQI 的许多优点,并指出了需要进一步验证的领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta dermato-venereologica
Acta dermato-venereologica 医学-皮肤病学
CiteScore
4.90
自引率
2.80%
发文量
210
审稿时长
6-12 weeks
期刊介绍: Acta Dermato-Venereologica publishes high-quality manuscripts in English in the field of Dermatology and Venereology, dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of Review articles in special areas, as well as short Letters to the Editor to stimulate debate and to disseminate important clinical observations. Acta Dermato-Venereologica has rapid publication times and is amply illustrated with a large number of colour photographs.
期刊最新文献
A Simple Feasible Method for Fixing Scalp Dressings. Commentary on: A European Consensus on the Consistent Use of the Term "Keratinocyte Cancer": Keratinocyte Cancer (KC) or Keratinocyte Skin Cancer (KSC) - Does the "S" Matter? Improvement of Skin Lesions in an Adult with CHILD Syndrome Treated with 2% Ketoconazole Cream. Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study. Erythematous Papules with Central Hyperkeratosis in Two Young Women: A Quiz.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1